Get the Stockscreener App
62.27
2.55%
1.55
Cytokinetics Inc stock is traded at $62.27, with a volume of 2.37M.
It is up +2.55% in the last 24 hours and down -1.97% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$60.72
Open:
$60.92
24h Volume:
2.37M
Relative Volume:
1.26
Market Cap:
$7.61B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-11.84
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-0.99%
1M Performance:
-1.97%
6M Performance:
+25.17%
1Y Performance:
+42.53%
1-Day Range:
$60.01
$62.57
1-Week Range:
$59.33
$63.00
52-Week Range:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
62.27 | 7.42B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Legato Capital Management LLC Takes Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Fisher Asset Management LLC Raises Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Is Priced For A Big MYQORZO Launch - Finimize
Rafferty Asset Management LLC Has $5.72 Million Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
CYTK Should I Buy - Intellectia AI
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
EVP at Cytokinetics (NASDAQ: CYTK) sells 886 shares after option exercise - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Director Lynne Parshall trims Cytokinetics (CYTK) stake in sale - Stock Titan
Cytokinetics to Participate in March Investor Conferences - Yahoo Finance
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With A 46.52% Potential Upside - DirectorsTalk Interviews
Cytokinetics, Incorporated $CYTK Stock Position Raised by Handelsbanken Fonder AB - MarketBeat
CYTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations - Yahoo Finance
A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback - simplywall.st
Monashee Investment Management LLC Buys Shares of 100,000 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Total Receivables : €1.54 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Inventories, Raw Materials & Components : €0.00 Mil (As of Sep. 2025) - GuruFocus
TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Inventories, Inventories Adjustments : €0.00 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) YoY Rev. per Sh. Growth : 250.00% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) FCF Margin % : -6,037.84% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Total Equity : €-444.00 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Research & Development : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus
HC Wainwright Estimates Cytokinetics Q3 Earnings - MarketBeat
Cytokinetics (HAM:KK3A) 1-Year ROIIC % : -84.62% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Investments And Advances : €246.07 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) COGS-to-Revenue : 51.27 (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Land And Improvements : €0.00 Mil (As of Sep. 2025) - GuruFocus
CYTK Technical Analysis & Stock Price Forecast - Intellectia AI
Cytokinetics (HAM:KK3A) Operating Cash Flow per Share : €-3.25 (TTM As of Sep. 2025) - GuruFocus
Decoding Cytokinetics Inc (CYTK): A Strategic SWOT Insight - GuruFocus
Cytokinetics (HAM:KK3A) Debt-to-EBITDA : -1.08 (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) EBITDA Margin % : -14,321.10% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Change In Prepaid Assets : €-7.08 Mil (TTM As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) 3-Year RORE % : 2.84% (As of Sep. 2025) - GuruFocus
Cytokinetics (CYTK) pivots to commercial growth with MYQORZO and heart failure pipeline - Stock Titan
Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Leerink Partners - MarketBeat
Cytokinetics (CYTK): Leerink Partners Raises Price Target | CYTK Stock News - GuruFocus
HC Wainwright Comments on Cytokinetics Q1 Earnings - MarketBeat
Needham raises Cytokinetics stock price target to $85 on trial outlook - Investing.com South Africa
Cytokinetics, Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance
Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns - simplywall.st
Cytokinetics (HAM:KK3A) Current Deferred Revenue : €1.37 Mil (As of Sep. 2025) - GuruFocus
BofA raises Cytokinetics stock price target to $67 on Myqorzo - Investing.com India
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug - Endpoints News
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz
Cytokinetics (HAM:KK3A) Sloan Ratio % : -38.57% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Other Stockholders Equity : €0.00 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) ROE % : 0.00% (As of Sep. 2025) - GuruFocus
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):